Tropisetron and its targets in Alzheimer's disease

Material type: 文書・図像類

Author: HASHIMOTO, Kenji

Publisher: INFORMA HEALTHCARE

Publication date: 2015-01

Material Format: Digital

Capacity, size, etc.: -

NDC: -

View All

Notes on use

Note (General)：: type:textAlzheimer's disease (AD) is the most common age-related neurodegenerative disorder.Despite this, there are no drugs for preventing the onset ...

Search by Bookstore

Holdings of Libraries in Japan

This page shows libraries in Japan other than the National Diet Library that hold the material.

List of Cooperating Institutions and Databases

Please contact your local library for information on how to use materials or whether it is possible to request materials from the holding libraries.

other

Chiba University Repository for Access to Outcomes from Research
Digital
You can check the holdings of institutions and databases with which Institutional Repositories DataBase(IRDB)(Institutional Repository) is linked at the site of Institutional Repositories DataBase(IRDB)(Institutional Repository).
Chiba University Repository for Access to Outcomes from Research

Search by Bookstore

Bibliographic Record

You can check the details of this material, its authority (keywords that refer to materials on the same subject, author's name, etc.), etc.

Digital

Material Type: 文書・図像類
Title: Tropisetron and its targets in Alzheimer's disease
Author/Editor: HASHIMOTO, Kenji
Author Heading: HASHIMOTO, Kenji
Publication, Distribution, etc.: INFORMA HEALTHCARE
Publication Date: 2015-01
Publication Date (W3CDTF): 2015-01
Periodical title: EXPERT OPINION ON THERAPEUTIC TARGETS
No. or year of volume/issue: 19 1
Volume: 19
Issue: 1
Pages: 1-5
ISSN (Periodical Title): ISSN : 1472-8222
Text Language Code: eng
Subject Heading: Alzheimer's disease
α7 Nicotinic receptor
β-Amyloid
Encenicline
5-HT3 receptor
Inflammation
Mild cognitive impairment
Tropisetron
Target Audience: 一般
Note (General): type:text
Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder.Despite this, there are no drugs for preventing the onset of AD. Preclinical studies suggest thatinteraction between amyloid-β peptides (Aβ) and the α7 nicotinic acetylcholine receptor (α7nAChR) plays a key role in AD pathology, and that α7 nAChR agonists could act as potentialtherapeutic drugs for AD. A recent study demonstrated that tropisetron, a potent α7 nAChRagonist and serotonin 5-HT3 receptor antagonist, also bound to the ectodomain of amyloidprecursor protein (APP). Furthermore, tropisetron promoted greater improvements in memorythan current AD therapeutic drugs, such as memantine and donepezil. Positron emissiontomography studies detected Aβ deposition and inflammation in the brains of subjects withamnestic mild cognitive impairment (MCI) before the onset of AD. Given the role of α7nAChR in Aβ deposition and inflammation, tropisetron represents an attractive potentialtherapeutic drug to delay or prevent MCI and AD. Additionally since this drug is usedinternationally to treat chemotherapy-induced emesis, its safety record is already known.
Access Restrictions: 限定公開
Related Material (DOI): 10.1517/14728222.2014.983901
Has Version (URI): URI
http://dx.doi.org/10.1517/14728222.2014.983901
Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）
https://irdb.nii.ac.jp
Original Data Provider (Database): 千葉大学 : 千葉大学学術成果リポジトリ